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Following a brain injury, the mobilization of reactive astrocytes is part of a complex
neuroinflammatory response that may have both harmful and beneficial effects. There
is also evidence that astrocytes progressively accumulate in the normal aging brain,
increasing in both number and size. These astrocyte changes in normal brain aging
may, in the event of an injury, contribute to the exacerbated injury response and poorer
outcomes observed in older traumatic brain injury (TBI) survivors. Here we present our
view that proton magnetic resonance spectroscopy (1H-MRS), a neuroimaging approach
that probes brain metabolism within a defined region of interest, is a promising technique
that may provide insight into astrocyte metabolic changes in the injured and aging brain in
vivo. Although 1H-MRS does not specifically differentiate between cell types, it quantifies
certain metabolites that are highly enriched in astrocytes (e.g., Myo-inositol, mlns), or
that are involved in metabolic shuttling between astrocytes and neurons (e.g., glutamate
and glutamine). Here we focus on metabolites detectable by 1H-MRS that may serve
as markers of astrocyte metabolic status. We review the physiological roles of these
metabolites, discuss recent 1H-MRS findings in the injured and aging brain, and describe
how an astrocyte metabolite profile approach might be useful in clinical medicine and
clinical trials.
Keywords: proton magnetic resonance spectroscopy, astrocytes, traumatic brain injury (TBI), aging, myo-inositol,
glutathione, glutamic acid, lactic acid
INTRODUCTION
Once thought to be merely part of the ‘‘glue’’ that holds together the neurons in the central
nervous system (CNS), astrocytes are now known to serve a variety of complex and essential
roles in CNS function. Astrocytes are intimately involved in regulating neurotransmission and
local cerebral blood flow, and in maintaining the osmotic, pH, and neurotransmitter homeostasis
of the extracellular environment in a manner that is essential for normal synaptic function.
They influence neuronal structure and function by releasing growth factors and cytokines, and
they play a critical role in brain energy metabolism, taking up glucose from the blood and
furnishing energy metabolites to neurons (Sofroniew and Vinters, 2010; Allaman et al., 2011).
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After a brain injury, molecular signals induce astrocyte
activation and migration to the site of injury. These reactive
astrocytes play two somewhat conflicting roles. One is protective,
by controling extracellular ionic and neurotransmitter balance,
providing essential metabolic substrates to neurons, scavenging
oxygen free radicals, and contributing to the formation of an
astroglial scar which protects the adjacent, relatively uninjured
tissue surrounding the brain lesion (Chen and Swanson, 2003).
The other may exacerbate injury pathology by playing a key role
in the neuroinflammatory response.
Astrocytes also progressively accumulate in the brain during
normal aging, increasing in both number and size (Cotrina and
Nedergaard, 2002). These aging-related astrocyte changes might,
in the event of an injury, contribute to the exacerbated injury
response and poorer outcomes observed in older traumatic brain
injury (TBI) patients (Popa-Wagner et al., 2011).
Given these critical roles of astrocytes in the function of the
normal and injured brain, the ability to monitor key aspects
of astrocyte metabolic status in the intact, living organism
would be of great value. We propose that proton magnetic
resonance spectroscopy (1H-MRS) provides this capability. 1H-
MRS is a non-invasive imaging technique that quantifies specific
brain metabolites within a defined brain region of interest
(ROI; Figure 1). Such metabolites can serve as biomarkers of
specific molecular and cellular mechanisms, which can be used
to monitor brain pathologies and effectiveness of treatment.
1H-MRS can be carried out on most magnetic resonance
imaging (MRI) scanners, and can quantify from 3 to 20 or
more metabolites in vivo depending on the magnetic field
strength and the selected pulse sequences. These metabolites
reflect various physiological processes including bioenergetics,
oxidative stress, neurotransmission, and neuroinflammation.
The high reproducibility of 1H-MRS data acquired in vivo has
been demonstrated in humans and rodents (Brooks et al., 1999;
Harris et al., 2012).
In this article, we advance the view that 1H-MRS is a
promising technique for non-invasive monitoring of astrocyte
metabolism in vivo. Although 1H-MRS does not specifically
differentiate between cell types, it can quantify metabolites
that are enriched in astrocytes or are related to astrocyte-
neuron metabolic shuttling. We identify five 1H-MRS-detectable
metabolites related to astrocyte metabolic status (Table 1),
review the known physiological roles of these compounds,
discuss recent 1H-MRS findings in the injured and aging
brain and describe how an astrocyte metabolite profile
approach might be useful in clinical medicine and clinical
trials.
COMPONENTS OF THE ASTROCYTE
METABOLITE PROFILE
Myo-inositol
Myo-inositol (mIns) is the most abundant isomer of inositol in
animal tissues. mIns is a component ofmembrane phospholipids,
plays a role in intracellular second messenger cascades, and is
an important organic osmolyte. Because the concentration of
FIGURE 1 | 1H-magnetic resonance spectra in the injured and aging
brain. (A–C) show spectra from rat cortex (2.7 × 1.3 × 2.7 mm3 ROI).
Images to the right show the location of each ROI. (A) Spectrum from an
un-injured adult male rat (3 months old). Major metabolite peaks visible at
9.4 T are labeled. (B) Spectrum from the same animal 1 day after a moderate
severity controlled cortical impact TBI. Acute post-injury changes are visible
including lower mIns and Glu and higher Gln and Lac. (C) Spectrum from an
un-injured aged rat (22 months old). More subtle metabolic changes in the
aging rat brain compared with younger controls include lower Glu and higher
mIns and Gln. The complex resonance pattern of GSH is not immediately
visible even at high magnetic field strengths but is detectable through digital
signal processing. (D) Spectrum from human white matter (5 × 5 × 15 mm3
ROI) of an adult male (20 years old) at 6 months post-TBI. The mIns, Lac, and
Glx peaks visible at 3 T are indicated. Human studies have reported elevated
mIns and Glx in TBI survivors from sub-acute to chronic time points (∼1 week
to 6 months post-injury; Brooks et al., 2000; Ashwal et al., 2004a,b; Kierans
et al., 2014). Abbreviations: ROI, region of interest; TBI, traumatic brain injury;
mIns, myo-inositol; Glu, glutamate; Gln, glutamine; Lac, lactate, Glx,
Glutamate + Glutamine; NAA, N = acetylaspartate; tCr, total creatine; tCho,
total choline; MM, macromolecules. Figure reproduced in part from Harris
et al. (2012) and Harris et al. (2014).
mIns is higher in astrocytes than in neurons (Brand et al., 1993),
mIns has widely been considered an astroglial marker. Due
to its high concentration in brain ranging from 4–10 µmol/g,
the mIns peak is readily detectable with in vivo 1H-MRS in
both laboratory animals (≥3 Tesla, T) and human subjects
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TABLE 1 | Summary of changes in astrocyte-relevant metabolites seen with 1H-MRS in vivo.
Aging TBI Aging References TBI References
mIns ↑ ↓ (early), ↑ (later) Chang et al. (1996), Reyngoudt et al. (2012), Zhang et al.
(2013) and Harris et al. (2014)
Schuhmann et al. (2003), Ashwal et al. (2004a,b), Xu et al. (2011),
Harris et al. (2012) and Kierans et al. (2014)
GSH ↓ ↓ Emir et al. (2011) Harris et al. (2012)
Gln ↑ ↑ Kaiser et al. (2005), Duarte et al. (2014) and Harris et al. (2014) Xu et al. (2011) and Harris et al. (2012)
Glu ↓ ↓ Kaiser et al. (2005), Duarte et al. (2014) and Harris et al. (2014) Schuhmann et al. (2003), Xu et al. (2011) and Harris et al. (2012)
Lac ∼ ↑ Urrila et al. (2004), Paban et al. (2010) and Harris et al. (2014) Ross et al. (1998), Ashwal et al. (2000), Schuhmann et al. (2003),
Lescot et al. (2010) and Harris et al. (2012)
Symbols and abbreviations: ↑ = increase, ↓ = decrease, ∼ = no change or mixed results, mIns = myo-inositol, GSH = glutathione, Gln = glutamine, Glu = glutamate,
Lac = lactate.
(≥1.5 T; Kreis et al., 1992; Pfeuffer et al., 1999; Blüml,
2013).
mIns plays an important role in osmotic control of astrocyte
cell volume. Decreased mIns is observed early after TBI
(Schuhmann et al., 2003; Xu et al., 2011; Harris et al., 2012;
Figure 1B), which may reflect mIns efflux from astrocytes as
a volume-regulatory strategy under conditions of edema, or
alternatively may reflect cell lysis and death (Zhao et al., 2003).
By contrast, pathologically activated astrocytes with larger cell
volumes tend to have increased mIns (Chang et al., 2013). Thus,
later (beginning at several days to weeks) in the progression
of the injury, increased mIns suggesting neuroinflammation
and reactive astrogliosis has been observed (Bitsch et al., 1999;
Schuhmann et al., 2003; Ashwal et al., 2004b; Filibian et al., 2012;
Harris et al., 2012; Kierans et al., 2014).
mIns levels also increase with normal brain aging in both
humans and animal models (Chang et al., 1996; Reyngoudt
et al., 2012; Zhang et al., 2013; Harris et al., 2014; Figure 1C),
suggesting an aging-related increase in activated astrocytes.
Therefore 1H-MRS might be useful to monitor the process of
‘‘inflamm-aging’’, the low-grade, chronic up-regulation of pro-
inflammatory signals in the normal aging brain (Franceschi et al.,
2007).
A link between increased mIns and astrocyte activation is
supported by invasive studies in animal models. In rats in
status epilepticus, hippocampal mIns was strongly correlated
with staining for two astrocyte markers, glial fibrillary acidic
protein (GFAP) and S100b (Filibian et al., 2012). In models of
Alzheimer’s disease and TBI, increased mIns corresponded with
increased GFAP staining within the same ROI (Chen et al., 2009)
and following the same time course (Schuhmann et al., 2003).
Moreover, an experimental anti-inflammatory treatment in a
mouse model of Alzheimer’s disease attenuated both the increase
in 1H-MRS-detectable mIns and the increase in GFAP-positive
astrocytes (Chen et al., 2012).
Data from humans are more limited, but also support a
link between mIns and astrocyte activation. In patients with
multiple sclerosis, GFAP-positive biopsies of demyelinating
lesions corresponded with elevated mIns measured in the same
location (Bitsch et al., 1999). In patients with schizophrenia,
mIns concentrations in the amygdala correlated with serum
levels of S100b (Rothermundt et al., 2007). A group of
high-likelihood Alzheimer’s disease patients had higher mIns
and higher postmortem GFAP staining than low-likelihood
controls, although in the combined sample GFAP and mIns
levels did not reach a statistical correlation (Murray et al.,
2014).
In sum, the evidence from 1H-MRS suggests that the mIns
changes observed in brain injury and aging reflect physiological
changes in astrocytes. As others have recently suggested (Rae,
2014), mIns is unlikely to be a marker for astrocyte cell
density alone since it is evident that pathological conditions
such as osmotic stress can alter intracellular concentrations
of mIns (Strange et al., 1994). Rather, we propose that early
decreases after a brain injury might reflect edema and/or cell
lysis. Increases seen in aging or at later intervals after a brain
injury likely reflect astrocyte activation and proliferation during
neuroinflammation.
Glutathione
The reduced form of glutathione (GSH) and ascorbate (Asc, or
vitamin C) are the twomost prominent endogenous antioxidants
in the CNS, protecting cells from damaging reactive oxygen
species and preserving essential cellular functions. While Asc
predominates in neurons, GSH concentrations are considerably
higher in astrocytes (Rice and Russo-Menna, 1998; Sun et al.,
2006). Therefore, GSH measured with 1H-MRS may provide
an in vivo marker of astrocyte antioxidant status. Additional
cellular functions of GSH include amino acid transport, acting
as a storage form of cysteine and a cofactor for redox reactions,
and protecting neuronal signal transduction (Brown, 1994;
Rae, 2014). GSH is routinely quantified in animal studies
using 1H-MRS at high magnetic fields, but is somewhat
more challenging to measure in humans, requiring specialized
acquisition strategies (Trabesinger and Boesiger, 2001; Terpstra
et al., 2003; Choi et al., 2011).
Brain GSH levels fall rapidly after TBI (Ansari et al., 2008a,b;
Harris et al., 2012), consistent with an early post-injury increase
in reactive oxygen species that depletes brain antioxidant reserves
(Kontos and Povlishock, 1986; Hall et al., 2010). Moreover, the
depletion of GSH is related to the severity of brain damage
(Harris et al., 2012; Di Pietro et al., 2014). In contrast, GSH levels
may increase in pathologies where astrocytes are chronically
activated and recruited. In a rat model of epilepsy, Filibian
et al. (2012) showed that elevated GSH concentrations in the
hippocampus were highly correlated with quantitative GFAP
staining, supporting the use of GSH as an in vivo marker of
astrocyte activation.
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Recent evidence from animal models and humans points
to lower GSH concentrations in the aging brain (Maher,
2005; Emir et al., 2011). Our group has found that the
regional pattern of GSH depletion in the aging brain differs
somewhat from that of Asc, suggesting that local populations
of astrocytes and neurons might be differentially sensitive to
oxidative stress during aging (Harris et al., 2014). In any
case, lower antioxidant levels suggest that the brain’s ability
to combat oxidative stress may be impaired in aging. Lower
GSH levels could contribute to an age-related decline in cellular
function and increase the brain’s susceptibility to insult (Maher,
2005). This notion is supported by studies of brain injury
in aged rats, which show more severe oxidative damage after
TBI compared with young adult animals (Shao et al., 2006;
Gilmer et al., 2010). Since antioxidant therapies are currently
under investigation for both brain trauma and aging, GSH
offers a potential in vivo marker to evaluate therapeutic target
engagement.
Glutamate and glutamine
Glutamate (Glu) serves as the major excitatory neurotransmitter
and is a precursor of γ-aminobutyric acid (GABA), the major
inhibitory neurotransmitter in the CNS. Glu is also closely
associated with glutamine (Gln) via the Glu-Gln cycle between
neurons and astrocytes. After its release from neuronal synapses,
Glu is taken up by nearby astrocytes, converted to Gln, then
transported back to neurons. Overall, brain Glu concentrations
range from 6–13 µmol/g and Gln from 2–4 µmol/g (Michaelis
et al., 1993; Petroff et al., 1995; Hurd et al., 2004). Although Glu
is found in all cells, glutamatergic neurons contain the highest
levels of Glu compared with other neuronal and glial cell types.
In contrast, because Gln synthetase is exclusive to astrocytes,
Gln levels are typically much higher in astrocytes. Therefore, 1H-
MRSmeasures of the relative concentrations of Gln and Glu may
be useful to infer changes in astrocyte populations or metabolic
status.
Studies by our group and others in animal models point
to rapidly increased Gln concurrent with decreased Glu after
brain injury (Lei et al., 2009; Xu et al., 2011; Harris et al., 2012;
Figure 1B), a finding consistent with injury-induced Glu release
from neurons followed by rapid uptake and conversion to Gln
by astrocytes i.e., the Glu-Gln cycle (Bartnik-Olson et al., 2013).
This likely reflects a critical role of astrocytes in helping to
limit the effects of Glu excitotoxicity in the acute post-injury
period.
In human and animal studies of the normal aging brain,
the Gln/Glu ratio increases progressively (Kaiser et al., 2005;
Duarte et al., 2014; Harris et al., 2014; Figure 1C), suggesting
a potential aging-related shift in the Glu-Gln cycle. This is
consistent with the finding of ∼30% lower flux through the Glu-
Gln cycle in healthy elderly humans compared with younger
adults (Boumezbeur et al., 2010). Whether such changes in
neuronal-astrocyte metabolic shuttling are responsible for age-
related declines in cognitive function remains an open question.
However, this could be addressed by studies that link 1H-MRS
measures of Glu and Gln with cognitive function in aging.
Lactate
According to the lactate shuttle hypothesis, glycolysis in
astrocytes generates lactate (Lac), which is then released from
the astrocytes to serve as a preferred fuel for neurons (Pellerin
and Magistretti, 1994). Lac is present in brain at approximately
0.5 µmol/g, which is approaching the lower threshold for
detection in animals and humans with standard 1H-MRS
techniques. However, in pathological conditions that alter
bioenergetics and result in increased Lac accumulation, the Lac
peak is easily detectable.
After a brain injury, an acutely increased energy demand
results in increased glycolysis, which along with impaired
respiratory function of mitochondria results in rapid Lac
accumulation. Elevated brain Lac after injury has been well
documented with spectroscopic methods (Ross et al., 1998;
Ashwal et al., 2000; Schuhmann et al., 2003; Lescot et al., 2010;
Harris et al., 2012; Figure 1B) and microdialysis (Nilsson et al.,
1990; Yokobori et al., 2011). Since Lac is produced by astrocytes
in areas of glutamatergic neuronal activity, astrocytes are likely
a major source of this Lac spike early after TBI. In support
of this view, Schuhmann et al. (2003) reported an increase in
Lac up to 24 h after TBI in animals which corresponded to
an increase in glutamate dehydrogenase (a Glu metabolizing
enzyme preferentially localized in astrocytes) in the ROI used
for 1H-MRS. Since Lac has been shown to strongly predict poor
outcomes after TBI in humans (Ashwal et al., 2000; Glenn et al.,
2003), the ability to track Lac accumulation in vivo could have
important clinical applications.
In contrast, reports on Lac concentrations in normal brain
aging are inconsistent, ranging from falls to increases (Urrila
et al., 2004; Paban et al., 2010; Emir et al., 2011; Zhang
et al., 2013; Duarte et al., 2014; Harris et al., 2014), perhaps
reflecting a varying capacity for bioenergetic homeostasis in
individual subjects or brain regions. Altered Lac levels in the
aging brain compared with younger adults implies a mismatch
between astrocytic glycolysis and neuronal oxidativemetabolism.
If metabolic coupling between neurons and astrocytes is indeed
altered in aging, this could impair the ability of the brain to
respond to insult andmight contribute to the poor outcomes seen
after TBI in older individuals.
CHALLENGES FOR MAGNETIC
RESONANCE SPECTROSCOPY?
We envision a future in which 1H-MRS biomarkers will
aid in prognostication and in selecting therapies to mitigate
the cognitive impairment seen with TBI, or the cognitive
decline seen with aging. Furthermore, these biomarkers will
provide a non-invasive means to track therapeutic target
engagement and efficacy. Although at present we can acquire
signals from numerous 1H-MRS biomarkers in animals,
there remains considerable opportunity for developing new
acquisition approaches to expand the repertoire of metabolites
routinely quantified in humans.
Using widely available spectroscopic acquisitions, Lac and
mIns are easily quantified in animal models and in humans.
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However, GSH, Glu, and Gln are more challenging, largely due
to overlapping signals. The issue of overlapping signals can
be resolved at higher magnetic field strengths; indeed, there is
already a proliferation of MRI scanners at 7 T and higher for
research use and some are advocating the use of fields greater
than 3 T for clinical investigation. An alternative approach is
to develop more sophisticated acquisition sequences such as
two-dimensional spectroscopy (Lin et al., 2015) and sequences
aimed at individual brain metabolites such as double quantum
acquisitions for GSH (Choi et al., 2011).
In addition to technical challenges of data acquisition,
challenges of data validation remain to be addressed before
1H-MRS biomarkers can be used in clinical applications. The
precise mechanisms underlying alteredmIns, GSH, Gln/Glu, and
Lac following brain injury or in aging are yet to be clarified.
Thus, the use of these metabolites as biomarkers of astrocyte
metabolic status needs to be further validated specifically in the
context of brain injury and aging, by comparing their levels
with other quantitative measures of astrocyte physiology. In
addition, there is currently little information available about the
possible contribution of other CNS cell types such as microglia
to the 1H-MRS profiles. Non-invasive 1H-MRS approaches in
animal models are well suited to addressing these questions, since
they permit intra-subject validation of pathological mechanisms
when in vivo scanning is followed by invasive histological and
biochemical analyses of the same tissue. Once validated in animal
models, 1H-MRS can form the basis for translational imaging
studies in humans, where it can be combined with measures
of cognitive function and other clinically relevant outcome
measures.
HOW WOULD AN ASTROCYTE
METABOLITE PROFILE BE USEFUL?
We have identified five 1H-MRS-detectable metabolites related
to astrocyte metabolic status. Although taken individually, each
metabolite might provide valuable information on individual
molecular or cellular mechanisms as discussed above, they
can also be considered in combination—as an astrocyte
metabolite profile. On the whole, the profiles of astrocyte-
relevant metabolite changes in brain aging and injury look
remarkably similar (Table 1) and are consistent with two possible
pathological mechanisms associated with aging and injury.
The first is bioenergetic disruption. Impaired mitochondrial
respiration is known to increase Lac accumulation and may
be related to increased Gln/Glu ratio in the aging and
injured brain since Glu is derived from α-ketoglutarate,
a TCA cycle intermediate. Moreover, bioenergetic deficit
can also result in reduced production of endogenous anti-
oxidants, including GSH. Disrupted mitochondrial respiration
can also cause increased reactive oxidative species, which
would further consume GSH. A second pathological mechanism
is inflammation, associated with astrocyte activation and
recruitment, which has also been reported in both aging and
injured brain. An increased astrocyte pool would result in
elevated mIns and could also yield elevated Gln/Glu.
Several lines of evidence suggest that a well-characterized
metabolite profile is likely to be useful as an overall biomarker
of injury severity and for prognostication, for stratifying patients
into trials, and for treatment selection and management.
Larger metabolite changes are associated with greater injury
severity and worse functional outcomes. For example, we have
shown in an animal model of TBI that the magnitude of change
in 1H-MRS-detectable metabolites is greater in tissue located
closer to the primary lesion site (Harris et al., 2012). Further
data from our laboratory show that Lac, GSH, and Glu, key
components of the astrocyte metabolite profile, measured within
a day of injury predicted the amount of subsequent tissue loss
at 2 weeks (Sharrock et al., 2015). In human TBI survivors,
Ashwal et al. found that greater Lac and mIns changes were
associated with poorer Glasgow coma scores and also with
poorer outcome (Ashwal et al., 1997, 2004b). Thus, the astrocyte
metabolite profile shows promise as a prognostic indicator for
brain injury.
The astrocyte metabolite profile might also be useful in
understanding cognitive decline in aging. As shown in Table 1,
the metabolite profile of the aging brain is similar to that of
a younger brain following TBI. The TBI profile is known to
be associated with poorer cognitive functioning (Ashwal et al.,
1997, 2004b). Thus, we might speculate that if this profile is
seen in aging, it could provide information related to declining
cognitive function that could be used to identify individuals
at risk for pathologies of aging or to stratify participants for
trials.
Finally, astrocyte-associated 1H-MRS biomarkers might be
used for treatment selection. To the extent that 1H-MRS-
detected metabolites are associated with cellular and molecular
mechanisms, changes observed in prognostic studies might
identify targets for therapeutic intervention. For example, an
elderly patient with cognitive impairment and lower GSH might
benefit from anti-oxidant therapy and a TBI patient with high
mIns might benefit from anti-inflammatory treatment. Finally,
these biomarkers could be used as pharmacodynamic indicators




1H-MRS is one of the few techniques that can non-invasively
assess the chemical concentrations and metabolic pathways of
the brain in living individuals. We propose that 1H-MRS-
detectable metabolites can serve as translational biomarkers of
certain aspects of brain health and pathology. Specifically, certain
metabolites seen on 1H-MRS promise insight into the metabolic
status of astrocytes in vivo.
The studies we have discussed here have largely focused
on 1H-MRS findings in normal brain aging or brain injury.
Although it is clear that the risk of brain injury is elevated
in older individuals and that outcomes in these patients are
significantly worse (Thompson et al., 2006), there is a dearth
of information on the combined effects of brain aging and
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brain injury. Thus, there is a critical need for further studies
aimed at better understanding the effects of aging on TBI
pathophysiology.
1H-MRS provides the ability to monitor specific aspects
of brain metabolic status in animals and humans as well as
across different biological conditions. Taken together, the
evidence we have presented suggests that 1H-MRS provides
a unique window onto astrocyte metabolic changes in
vivo. Given the many essential roles of astrocytes in brain
function, we believe that the ability to monitor astrocyte
metabolism in vivo will provide important insights into
pathological changes in the aged and injured brain—a
critical step for developing and translating therapies to
improve long-term outcomes in this vulnerable patient
population.
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